GlassScriptPhysician profile
David T Kira
NPI 1689696411
$5,226.49
in general payments reported to CMS, 2019-2025
28 companies · $1,094 in 2025
The $1,094 reported for 2025 was more than what 79% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $423 · 2020: $104 · 2021: $423 · 2022: $1,394 · 2023: $736 · 2024: $1,054 · 2025: $1,094.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,883.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $1,249.75 | 2019-2025 | |
| Alcon Vision LLC | $1,034.89 | 2019-2025 | Clareon, Clareon Panoptix Pro, Acrysof Iq Vivity |
| Mallinckrodt Hospital Products INC. | $580.96 | 2021-2025 | Acthar |
| Oyster Point Pharma, INC. | $303.92 | 2022-2025 | Tyrvaya |
| Dompe US, INC. | $224.00 | 2021-2025 | Oxervate |
| Abbvie INC. | $197.87 | 2022-2025 | |
| Rxsight INC | $172.10 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Novartis Pharmaceuticals Corporation | $147.22 | 2019-2022 | |
| New World Medical,INC. | $131.95 | 2025 | Via360, Ahmed Glaucoma Valve, Clearpath |
| Sun Pharmaceutical Industries INC. | $130.56 | 2019-2025 | |
| Rayner Intraocular Lenses Limited | $115.64 | 2023-2024 | Omidria, Rayone Aspheric, Rayone Emv |
| Ani Pharmaceuticals, INC. | $114.68 | 2022-2023 | Purified Cortrophin Gel |
| Amgen INC. | $90.21 | 2024-2025 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $87.85 | 2022-2023 | Tecnis Iol |
| Allergan, INC. | $82.91 | 2020-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $79.40 | 2024-2025 | Idose, Idosetr |
| Sight Sciences, INC. | $63.39 | 2021-2025 | Tearcare System, Omni Surgical System, Sion Surgical Instrument |
| Thea Pharma INC. | $60.70 | 2023-2025 | Iyuzeh |
| Tarsus Pharmaceuticals, INC. | $60.54 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $59.47 | 2019 | |
| Aerie Pharmaceuticals, INC. | $54.09 | 2019-2021 | |
| Astellas Pharma US INC | $42.91 | 2025 | Izervay |
| Eyepoint US, INC. | $37.81 | 2021 | |
| Carl Zeiss Meditec USA, INC. | $27.49 | 2023 | Lumera 700 |
| Harrow Eye, LLC | $24.59 | 2024 | Vevye |
| Optos, INC. | $20.13 | 2022 | |
| Horizon Therapeutics Plc | $15.77 | 2023 | Tepezza |
| Kala Pharmaceuticals, INC. | $15.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kira listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.